Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEO Agent (MRI)
- Development stage
- Preclinical
- Lead developer
- NeoIndicate
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
NEO Agent (MRI) is a gadolinium-based molecular imaging contrast agent developed by NeoIndicate for the detection and characterization of brain tumors, specifically gliomas. It targets Protein Tyrosine Phosphatase Mu (PTPµ, also known as PTPRM), a biomarker that is proteolytically cleaved and becomes exposed in the tumor microenvironment of multiple cancer types, including glioblastoma. By binding to this tumor-specific form of PTPµ, the agent enhances MRI detection, potentially allowing for better visualization of tumor margins and infiltrative cells that are often missed by standard contrast agents.
- Other names
- PTPµ-targeted gadolinium-based contrast agent
02
Targets
PTPRM
Beyond the preview
Go deeper on NEO Agent (MRI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEO Agent (MRI).